SLC22A2 and renal cell adenocarcinoma: Treatment of RCC cell lines with the hypomethylating agent decitabine and the histone deacetylase inhibitor vorinostat increased the expression of OCT2 and sensitized RCC cells to the OCT2 substrate oxaliplatin, both in vitro and in xenografts [94,95].